X4 Pharmaceuticals Secures $85 Million in Private Placement
X4 Pharmaceuticals, a company dedicated to enhancing the lives of individuals with rare immune diseases, has successfully closed an upsized private placement. This offering raised a total of $85 million through the issuance of 11,040,776 shares of common stock along with pre-funded warrants for an additional 48,852,772 shares. Originally targeting only $60 million, the company increased the offering to accommodate an investor with existing rights.
Investors and Funding Details
The financing round was led by Coastlands Capital, backed by prominent investors like Empery Asset Management, Bain Capital Life Sciences, and New Enterprise Associates. Their participation reflects confidence in X4's innovative approach to treating rare diseases.
Utilization of Funds for Development
The proceeds from this private placement will primarily support the continued development of mavorixafor, X4's core therapeutic candidate, particularly its potential approval for chronic neutropenia. Additionally, these funds will aid in the commercialization of X4's product WHIM.
Regulatory Compliance and Future Plans
The securities issued are part of a transaction that does not involve a public offering and remain unregistered under the Securities Act of 1933. X4 Pharmaceuticals is committed to complying with regulatory requirements, including the filing of a registration statement with the Securities and Exchange Commission to facilitate the resale of these shares.
About X4 Pharmaceuticals' Commitment
X4 Pharmaceuticals focuses on developing and marketing innovative therapies for patients suffering from rare diseases of the immune system. Their lead product, mavorixafor, is an orally available CXCR4 antagonist currently marketed in the U.S. as XOLREMDI for its first indication. The company is actively assessing additional applications for this drug and is conducting a pivotal Phase 3 clinical trial named 4WARD, aimed at individuals with specific chronic neutropenic disorders.
Background and Innovation
With its headquarters situated in Boston, X4 is at the forefront of developing therapies addressing the unmet needs of patients with rare immune diseases. This innovative approach leverages specialized knowledge in CXCR4 biology and immune system mechanisms.
Investor Relations
Candice Masse, a representative from X4 Pharmaceuticals, is the point of contact for investors interested in this significant fundraising initiative. For further inquiries, she can be reached at (978) 879-7273.
Frequently Asked Questions
What is the amount raised in the latest funding for X4 Pharmaceuticals?
X4 Pharmaceuticals successfully raised $85 million in their recent private placement.
Who were the primary investors in this placement?
The funding was led by Coastlands Capital and included several notable investors such as Empery Asset Management and Bain Capital Life Sciences.
What will the funds be used for?
The proceeds will be primarily utilized for the development of mavorixafor and the commercialization of WHIM.
Is the offering part of a public or private placement?
The private placement is a transaction that is not considered a public offering.
How can interested investors contact X4 Pharmaceuticals?
Interested investors can reach out to Candice Masse at (978) 879-7273 for inquiries regarding the placement.
